BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34958511)

  • 1. Molecular testing for melanocytic tumors: a practical update.
    Andea AA
    Histopathology; 2022 Jan; 80(1):150-165. PubMed ID: 34958511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular testing in melanoma for the surgical pathologist.
    Andea AA
    Pathology; 2023 Mar; 55(2):245-257. PubMed ID: 36653236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular diagnostics for ambiguous melanocytic tumors.
    Shahbain H; Cooper C; Gerami P
    Semin Cutan Med Surg; 2012 Dec; 31(4):274-8. PubMed ID: 23174498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements.
    Chandler WM; Rowe LR; Florell SR; Jahromi MS; Schiffman JD; South ST
    Arch Pathol Lab Med; 2012 Aug; 136(8):947-55. PubMed ID: 22849744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between histologic assessment and fluorescence in situ hybridization using MelanoSITE in evaluation of histologically ambiguous melanocytic lesions.
    Zembowicz A; Yang SE; Kafanas A; Lyle SR
    Arch Pathol Lab Med; 2012 Dec; 136(12):1571-9. PubMed ID: 22480223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
    Lezcano C; Jungbluth AA; Busam KJ
    Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitotically Active Nevus and Nevoid Melanoma: A Clinicopathological and Molecular Study.
    Mesbah Ardakani N; Singh S; Thomas C; Van Vliet C; Harvey NT; Calonje JE; Wood BA
    Am J Dermatopathol; 2021 Mar; 43(3):182-190. PubMed ID: 32649342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescence in situ hybridization for ambiguous melanocytic tumors.
    Gammon B; Gerami P
    Histol Histopathol; 2012 Dec; 27(12):1539-42. PubMed ID: 23059884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferation indices correlate with diagnosis and metastasis in diagnostically challenging melanocytic tumors.
    Al-Rohil RN; Curry JL; Torres-Cabala CA; Nagarajan P; Ivan D; Aung PP; Lyons GF; Bassett RL; Prieto VG; Tetzlaff MT
    Hum Pathol; 2016 Jul; 53():73-81. PubMed ID: 27004944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases.
    Vergier B; Prochazkova-Carlotti M; de la Fouchardière A; Cerroni L; Massi D; De Giorgi V; Bailly C; Wesselmann U; Karlseladze A; Avril MF; Jouary T; Merlio JP
    Mod Pathol; 2011 May; 24(5):613-23. PubMed ID: 21151100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.
    Wiesner T; Kutzner H; Cerroni L; Mihm MC; Busam KJ; Murali R
    Pathology; 2016 Feb; 48(2):113-31. PubMed ID: 27020384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescence in-situ hybridization analysis for melanoma diagnosis.
    Senetta R; Paglierani M; Massi D
    Histopathology; 2012 Apr; 60(5):706-14. PubMed ID: 22007736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular testing to differentiate melanoma from benign nevi: The gold standard limitation.
    Bitterman A
    J Am Acad Dermatol; 2016 Oct; 75(4):849-850. PubMed ID: 27646748
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of New Techniques in Addition to IHC Applied to the Diagnosis of Melanocytic Lesions, With Emphasis on CGH, FISH, and Mass Spectrometry.
    Nagarajan P; Tetzlaff MT; Curry JL; Prieto VG
    Actas Dermosifiliogr; 2017; 108(1):17-30. PubMed ID: 27344067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular diagnosis of melanocytic tumors].
    Bauer J
    Hautarzt; 2016 Jan; 67(1):59-63. PubMed ID: 26589514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FISH as an effective diagnostic tool for the management of challenging melanocytic lesions.
    Moore MW; Gasparini R
    Diagn Pathol; 2011 Aug; 6():76. PubMed ID: 21834951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation of melanoma and benign nevi by fluorescence in-situ hybridization.
    Hossain D; Qian J; Adupe J; Drewnowska K; Bostwick DG
    Melanoma Res; 2011 Oct; 21(5):426-30. PubMed ID: 21900793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordance in the histopathologic diagnosis of difficult melanocytic neoplasms in the clinical setting.
    Lodha S; Saggar S; Celebi JT; Silvers DN
    J Cutan Pathol; 2008 Apr; 35(4):349-52. PubMed ID: 18333894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular testing of borderline cutaneous melanocytic lesions: SNP array is more sensitive and specific than FISH.
    Carter MD; Durham AB; Miedema JR; Harms PW; Chan MP; Patel RM; Lowe L; Fullen DR; Hristov AC; Wang M; Andea AA
    Hum Pathol; 2019 Apr; 86():115-123. PubMed ID: 30576704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Melanoma Diagnosis Update: Gene Fusion, Genomic Hybridization, and Massively Parallel Short-Read Sequencing.
    Lang UE; Yeh I; McCalmont TH
    Clin Lab Med; 2017 Sep; 37(3):473-484. PubMed ID: 28802496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.